bicyclo[2.2.1]heptane-1-carbaldehyde | 2094-67-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: bicyclo[2.2.1]heptane-1-carbaldehyde
• 英文别名: Norbornan-1-carboxaldehyd
• CAS: 2094-67-9
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: HWSMGEOQSJOPQN-UHFFFAOYSA-N

物化性质

• 沸点：
  173.1±9.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bicyclo[2.2.1]heptane-1-carbaldehyde 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.5h， 以95%的产率得到1-(羟甲基)双环(2.2.1)庚烷
  参考文献：
  名称：

  1-降冰片基锂作为前驱体用于合成新型有机 1-双环 [2.2.1] 庚烷衍生物和改进 1-氯-双环 [2.2.2] 辛烷的制备

  摘要：

  摘要 描述了一种合成 1-氯-双环 [2.2.2] 辛烷的改进策略，其中关键化合物 1-降冰片基取代甲酸乙酯 (3) 或 1-降冰片基甲醛 (7) 由 1-降冰片基锂 (1) 制备。 . 后者似乎是合成各种有机桥头取代衍生物的有用前体。

  DOI：

  10.1080/00397919508011771
• 作为产物：
  描述：

  1-(羟甲基)双环(2.2.1)庚烷 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以74%的产率得到bicyclo[2.2.1]heptane-1-carbaldehyde
  参考文献：
  名称：

  Ring-Expansion of Bridgehead Aldehydes with 1-Adamantanecarbonyl Cation or Benzoyl Trifluoromethanesulfonate: A New Route to Bicyclic and Tricyclic 1,2-Diols

  摘要：

  在三氟甲磺酸存在下，桥头醛与由 1-金刚烷阳离子和一氧化碳生成的 1-金刚烷羰基阳离子或与三氟甲磺酸苯甲酰酯发生酰化反应，会使醛环扩张一个碳原子。将反应混合物加水处理后，可得到在邻接碳上含有酰氧基的桥头醇，皂化后可得到邻接二醇，总产率很高。例如，双环[2.2.1]庚烷-1-甲醛可生成双环[2.2.2]辛烷-1,2-二醇，而其他方法很难获得这种物质。

  DOI：

  10.1055/s-1987-28022

文献信息

• Use of Mineral/Organic Composite Material in the Form of an Ultraviolet Radiation Protective Agent
  申请人：Daniele Stephane

  公开号：US20090104135A1

  公开（公告）日：2009-04-23

  The invention relates to the use of composite material which comprises nanoparticles of a least one metal derivative and at least one organic sunscreen agent which is chemically bound with said particles in a covalent manner in the form of an ultraviolet radiation protective agent containing the inventive composite material. Cosmetic ultraviolet radiation protective compositions comprises said mixture are also disclosed.

  该发明涉及使用复合材料，该复合材料包括至少一种金属衍生物的纳米颗粒和至少一种有机防晒剂，该有机防晒剂以共价方式与所述颗粒化学结合，形成一种含有所述创新复合材料的紫外辐射防护剂。还公开了包含所述混合物的化妆品紫外辐射防护组合物。
• [EN] ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS<br/>[FR] ANALOGUES D'ATAZANAVIR (ATV) POUR TRAITER DES INFECTIONS PAR LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2018145021A1

  公开（公告）日：2018-08-09

  The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, the compound of formula (I) for use in therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I. Preferred compounds are N-[(2S) -1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino) -3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(phenyl) methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate atazanavir (ATV) analogues substituted by several heterocycles, such as e.g. pyrazole (Rl); e.g. oxetane (substituent of X2); e.g. pyridine or pyrimidine (X1); e.g. piperazine or 3,8-diazabicyclo[3.2.1]octan (X2).

  该发明提供了一种如下式的化合物：或其药学上可接受的盐。该发明还提供了包含如下式化合物的药物组合物，制备如下式化合物的方法，以及利用如下式化合物治疗HIV病毒增殖、治疗艾滋病或延缓哺乳动物艾滋病症状发作的治疗方法中使用的如下式化合物。首选化合物是N-[(2S)-1-[2-[(2S,3S)-2-羟基-3-[[(2S)-2-(甲氧羰基氨基)-3,3-二甲基丁酰]氨基]-4-苯基丁基]-2-[(苯基)甲基]肼基]-3,3-二甲基-1-氧丁酸-2-基]氨基甲酸酯阿扎那韦（ATV）类似物，其被若干杂环取代，例如吡唑（R1）；例如氧杂环（X2的取代基）；例如吡啶或嘧啶（X1）；例如哌嗪或3,8-二氮杂双环[3.2.1]辛烷（X2）。
• Pyrazole derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040116475A1

  公开（公告）日：2004-06-17

  A compound of the formula (I): 1 wherein R 1 is hydrogen or lower alkyl; R 2 is lower alkyl, etc.; R 3 is lower alkoxy, etc.; R 4 is hydroxy, etc.; X is O, S, etc.; Y is CH or N; Z is lower alkylene or lower alkenylene; and m is 0 or 1; or salts thereof, which are useful as a medicament.

  式（I）的化合物： 其中R1为氢或较低的烷基； R2为较低的烷基，等等； R3为较低的烷氧基，等等； R4为羟基，等等； X为氧、硫等； Y为CH或N； Z为较低的烷基烯基或较低的烯基烷基；以及 m为0或1；或其盐，可用作药物。
• [EN] CARBOCYCLIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE CARBOCYCLIQUES
  申请人：INCEPTION 4 INC

  公开号：WO2017222914A1

  公开（公告）日：2017-12-28

  This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的Formula (I)的碳环脯氨酰胺衍生物，以及在预防（例如，延缓或降低发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）和相关疾病方面有用的药用盐、溶剂化合物、盐的溶剂化合物和前药。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜脉络膜病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜脉络膜病变以及视网膜或光感受器细胞的方法，包括：给予所述发明的化合物的治疗有效量。本发明的化合物是HTRA1的抑制剂。因此，本发明的化合物在预防和治疗通过HTRA1（全部或部分）介导的广泛疾病方面有用。本发明的化合物还可用于抑制眼睛或关节炎或相关疾病部位的HTRA1蛋白酶活性。
• BICYCLIC PYRAZOLE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1659123A1

  公开（公告）日：2006-05-24

  A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A1 and A2 indicate a double bond (A1=A2), etc.; A1 represents a group represented by the formula C(R2), etc.; A2 represents a group represented by the formula C(R4), etc.; R2 represents hydrogen, optionally substituted alkyl, etc.; R4 represents hydrogen, optionally substituted alkyl, etc.; R6 represents hydrogen, optionally substituted aryl, etc.; and -Y represents, e.g.; a group represented by the formula (A): (A) (wherein ml is 0, 1, 2, or 3; and R7 is absent, or one or two R7's are present and each independently represents optionally substituted alkyl, etc.).]

  以下式(I)表示的化合物、前药或药用可接受的盐。这些化合物具有高DPP-IV抑制活性，并且在安全性、非毒性等方面进行了改进。(I) [在公式中，R1代表氢，可选地取代烷基等；A1和A2之间的实线和虚线表示双键(A1=A2)等；A1代表由公式C(R2)等表示的基团；A2代表由公式C(R4)等表示的基团；R2代表氢，可选地取代烷基等；R4代表氢，可选地取代烷基等；R6代表氢，可选地取代芳基等；-Y代表例如；由公式(A)表示的基团：(A)(其中ml为0、1、2或3；R7缺失，或存在一个或两个R7，每个独立地代表可选地取代烷基等)。]